NecstGen

Where are most Cell and Gene Therapy developers located? The booming biotechnology sector has seen remarkable growth, particularly in Cell and Gene Therapy, which holds immense promise for meeting patients' unmet needs. With the rise of private equity investments, cross-continent acquisitions, and record-level IPOs, it's crucial to understand the geographical distribution of these innovative developers. Our goal at NecstGen is to map out these key players and hubs to provide a comprehensive overview of the industry landscape across Europe. NecstGen is proud to present the latest update to our European Cell & Gene Therapy Companies map, sharing insights into the ATMP landscape in Europe. Our updated map is more than just a visual representation of data. It's a bridge that connects major hubs and helps us understand the geographical spread of cell and gene therapy companies. By visualizing this data, we aim to foster a sense of community, support industry growth, and drive the development of next-generation therapies. Explore our map to gain valuable insights and connect with key players in the industry here: https://lnkd.in/gyJpXueh If your organization still needs to be listed, please contact us here: www.necstgen.com/contact. Together we challenge today’s possibilities and enable the unthinkable. Leiden Bio Science Park Cambridge Biomedical Campus Utrecht Science Park BioAlps - Swiss Health Valley London BioScience Innovation Centre (LBIC) Oxfordshire Local Enterprise Partnership (OxLEP) Pivot Park Amsterdam Science Park Utrecht Science Park Tech Park Basel Medicen Paris Region Lyonbiopôle Auvergne-Rhône-Alpes Institut Imagine Ideon Science Park #CGT #celltherapy #genetherapy #ATMP

What does it take to bring a cell or gene therapy to patients? Have you ever wondered what it means to develop viral vectors, cell therapies, (ex vivo) gene therapies, and more? Watch the video. Bringing a product from R&D to production takes work. When developing a cell therapy, for example, we very closely examine the processes that our client has developed so far. We go through them, identify the critical process steps, and adjust them to achieve a GMP-compliant manufacturing process. But what is the most critical aspect of it all? We operate at the edge of scientific discovery, always keeping the patient at the centre. NecstGen helps academic and industrial Cell and Gene Therapy developers enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC, and regulatory affairs in a 4,000 m2 development and GMP manufacturing facility. Watch the video and start exploring how we bring CGTs closer to the patients who need them. #celltherapy #genetherapy #viralvector #cdmo

We are proud to share that our recurrent customer Pan Cancer T secured € 4.25 million seed extension and continues its path to the clinic to treat solid tumors! Press release: Rotterdam and Leiden, Netherlands, July 17, 2024 – NecstGen, a non-profit CDMO, and Pan Cancer T, a company developing a TCR-T cell product (PCT1:CO-STIM) for the treatment of triple negative breast cancer, announce further projects.   This new agreement with Pan Cancer T builds directly on the solid foundation established in previous collaborations between both organisations. Following a successful technology transfer and proof-of-concept scale-up, both parties are happy to announce that more activities will be performed by NecstGen at its state-of-the-art facility for Cell and Gene Therapy development and manufacturing located in Leiden.   Rachel Abbott, CEO, Pan Cancer T commented, “Successfully completing our latest funding round will accelerate our path to the clinic and treating patients. CMC development is a critical component to realising this ambition. We recognise in NecstGen a partner committed to reducing the costs of development and manufacturing whilst maintaining commitment to quality.”   The companies will continue to undertake the process and analytical development of Pan Cancer T’s novel Cell Therapy. Led by Melissa Van Pel, Head of Cell Therapy, NecstGen will utilise its large equipment portfolio and expert team to progress the process and assays required for PCT1:CO-STIM to be successfully manufactured.   This continued collaboration demonstrates NecstGen’s capability to scale and enhance processes as its partnerships evolve to enable bridging early research and clinical applications, including GMP manufacturing.    Paul Bilars, CEO, NecstGen, said, “I am delighted with my team’s performance in our partnership with Pan Cancer T to date, demonstrating what NecstGen can contribute to organisations in Cell and Gene Therapy. NecstGen now routinely receives feedback that we are offering partners a competitive cost basis. This is core to our vision as an organisation. Maximising the budget of all organisations involved in Cell and Gene Therapy will accelerate therapies reaching patients and benefiting society.” Full press release: https://lnkd.in/eYpnTgRX For more information please contact:   Pan Cancer T - Rachel Abbott, CEO NecstGen - Tristan Pritchard-Meaker, Head of Business Development

We're #hiring a new Technician Viral Vector in Leiden, South Holland. Apply today or share this post with your network.

We're #hiring a new Maintenance Technician – permanent and temporary position. in Leiden, South Holland. Apply today or share this post with your network.

A few days ago, our team, comprising Melissa Van Pel, David W., Yasmin Habani, Conor Vogelzang, and Tristan Pritchard-Meaker, visited bioMérieux in Lyon to strengthen our partnership further and explore the forefront of Cell and Gene Therapy (CGT). We explored current trends and developments within the CGT field during our visit. Additionally, we were given a tour of bioMérieux’s state-of-the-art specialist manufacturing facilities, where we observed their advanced processes firsthand! Our collaborative session on Quality Control (QC) applications in CGT was a significant highlight. We shared our feedback and user experiences, identified unmet needs in our field, and discussed the potential to further support and enhance QC processes. This exchange of ideas is crucial for pushing the boundaries of what’s possible in CGT. Melissa gave an insightful presentation on CGT/NecstGen projects, showcasing our ongoing initiatives and future goals. Her presentation underscored our commitment to innovation and excellence in the field. We look forward to our continued collaboration! #cellandgenetherapy #qualitycontrol #innovation #partnership #bioMérieux

We're #hiring a new Warehouse & Logistics Operator in Leiden, South Holland. Apply today or share this post with your network.

NecstGen is looking for passionate individuals to fill key positions in our Facilities and Services team. As part of our mission, you will not only support innovative cell and gene therapies but also become a co-author of our pioneering story in Regenerative Medicine. Please share this with anyone in your network who might be the perfect fit for our dynamic team! We're hiring for several roles, including Head of Facilities and Services, Maintenance Technician, Support Engineer (Summer), and a Warehouse Logistics Operator. In addition, we're offering an internship in Facilities and Services to work in an exciting facility with modern, state-of-the-art techniques. At NecstGen, you'll thrive in a supportive environment that values your well-being and professional development. More than a job, we offer you the chance to make a tangible impact on people's health and happiness. View and apply to our open vacancies on our website: https://lnkd.in/gXDv4YYh #hiring #facilities #services #technician #engineering

Today, we started with an inspiring presidential plenary session at the ISSCR 2024 Annual Meeting in Hamburg, Germany. This gathering brings together  4,000 international scientists, making it a hub of innovation and collaboration in stem cell research and regenerative medicine. NecstGen is excited to attend this event and connect with innovators, exchange ideas, and stay at the forefront of scientific advancements. We're particularly looking forward to the diverse program, including plenary and concurrent sessions, science spotlights, and innovation showcases, which align perfectly with our mission to support and accelerate cutting-edge research. Join us at booth #702 to connect with our team members Tristan Pritchard-Meaker, Óscar Bártulos, André Soares, and Sophia Kolbe. Let's discuss how we can accelerate your projects and drive meaningful advancements together. #ISSCR2024 #stemcells #regenerativemedicine #celltherapy #genetherapy #CGT

NecstGen is proud to announce a collaboration with Dr. Debby Gawlitta of the Department of Oral and Maxillofacial Surgery & Special Dental Care at UMC Utrecht to develop an innovative bone regeneration therapy using mesenchymal stromal cell-derived spheroids. Dr. Gawlitta’s research has demonstrated promising results in preclinical studies, showcasing successful endochondral bone regeneration in rat and goat models. Through this collaboration, NecstGen will support Dr. Gawlitta’s project by offering development support of this innovative therapy. “We are excited about the potential of this collaboration with Dr. Gawlitta,” said Paul Bilars, CEO of NecstGen. “Our mission is to accelerate the delivery of innovative medicinal products to patients. This project exemplifies our commitment to support the next generation of therapies that can significantly impact patients’ lives.” Dr. Gawlitta has received a RegMed XB/Dutch Cardiovascular Alliance Thematic Tech Transfer Voucher sponsoring this collaborative activity to further develop her innovative findings into treatments. Read the full press release here: https://lnkd.in/ejWrqbCd